In just three weeks, Acurian helped two T2D clinical trials get back on track. The sponsor won the race to market against two major competitors.

Endocrinology

Diabetes/Obesity / Type 2 Diabetes

The sponsor began a fierce race in the diabetes space with its phase III clinical trials for a new class of drug for type 2 diabetes. The competition was stiff, but the race was worth winning. If approved, sales were projected to hit $1.5 billion by 2018 in a market for type 2 diabetes drugs that will nearly double to $50 billion by 2022.

Read More »